MedTrace Logo

Impact of Carrier Solutions for House Dust Mite Allergen on Allergic Reactions

NCT05245175 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2024-10-15

No results posted yet for this study

Summary

Single-blind, within-block randomized, clean-air-controlled study to assess the effect of lactose and sodium chloride particles in patients with allergic rhinitis on nasal symptoms when challenged in the Fraunhofer Allergen Challenge Chamber

Conditions

  • Allergic Rhinitis

Interventions

OTHER

Sodium chloride particles

Patients are exposed to sodium chloride particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.

OTHER

Lactose particles

Patients are exposed to lactose particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.

OTHER

Clean air

Patients are exposed to clean air for 4 hours in the Fraunhofer Allergen Challenge Chamber.

OTHER

Sodium chloride particles with house dust mite

Patients are exposed to sodium chloride particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.

OTHER

Lactose particles with house dust mite

Patients are exposed to lactose particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.

Sponsors & Collaborators

  • Fraunhofer-Institute of Toxicology and Experimental Medicine

    lead OTHER

Principal Investigators

  • Jens M Hohlfeld, Prof. Dr. · Fraunhofer Institute for Toxicology and Experimental Medicine ITEM

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-22
Primary Completion
2022-04-13
Completion
2022-04-13

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05245175 on ClinicalTrials.gov